Fabian Yuh Shiong Kong

Fabian Yuh Shiong Kong

Auto-generated profile, based on publicly available information

Fabian Yuh Shiong Kong

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FKF. Y. S. Kong
F. Y. S. Kong
STS. N. Tabrizi
S. N. Tabrizi
MLM. Law
M. Law
LVL. A. Vodstrcil
L. A. Vodstrcil
MCM. Chen
M. Chen
JHJ. S. Hocking
J. S. Hocking
Background. There has been recent debate questioning the efficacy of azithromycin for the treatment of urogenital chlamydia infection. We conducted a meta-analysis to compare the efficacy of 1 g azithromycin with 100 mg doxycycline twice daily (7 days) for the treatment of urogenital chlamydia infection. Methods. Medline, PubMed, Embase, Cochrane Controlled Trials Register, Cochrane reviews, and Cumulative Index to Nursing and Allied Health Literature were searched until 31 December 2013. Randomized controlled trials comparing azithromycin with doxycycline for the treatment of genital chlamydia with evaluation of microbiological cure within 3 months of treatment were included. Sex, diagnostic test, follow-up time, attrition, patient symptomatic status, and microbiological cure were extracted. The primary outcome was the difference in efficacy at final follow-up. Study bias was quantitatively and qualitatively summarized. Results. Twenty-three studies were included evaluating 1147 and 912 patients for azithromycin and doxycycline, respectively. We found a pooled efficacy difference in favor of doxycycline of 1.5% (95% confidence interval [CI], −.1% to 3.1%; I2 = 1.9%; P = .435; random effects) to 2.6% (95% CI, .5%–4.7%; fixed effects). Subgroup analyses showed that the fixed effects pooled efficacy difference for symptomatic men was 7.4% (95% CI, 2.0%–12.9%), and the random effects was 5.5% (95% CI, −1.4% to 12.4%). Conclusions. There may be a small increased efficacy of up to 3% for doxycycline compared with azithromycin for the treatment of urogenital chlamydia and about 7% increased efficacy for doxycycline for the treatment of symptomatic urethral infection in men. However, the quality of the evidence varies considerably, with few double-blind placebo-controlled trials conducted. Given increasing concern about potential azithromycin failure, further well-designed and statistically powered double-blind, placebo-controlled trials are needed.

17 November 2020 in Sexually Transmitted Infections
Verified
Journal Article
Open access
PDF file
JCJacqueline Coombe
Jacqueline Coombe
FKFabian Yuh Shiong Kong
Fabian Yuh Shiong Kong
HBHelen Bittleston
Helen Bittleston
HWHenrietta Williams
Henrietta Williams
JTJane E. Tomnay
Jane E. Tomnay
JHJane S Hocking
Jane S Hocking
Introduction Australia recorded its first case of COVID-19 in late January 2020. On 22P March 2020, amid increasing daily case numbers, the Australian Government implemented lockdown restrictions to help ‘flatten the curve’. Our study aimed to understand the impact of lockdown restrictions on sexual and reproductive health. Here we focus on sexual practices. Methods An online survey was open from the 23PP April 2020 to 11P May 2020. Participants were recruited online via social media and other networks and were asked to report on their sexual practices in 2019 and during lockdown. Logistic regression was used to calculate the difference (diff) (including 95% CIs) in the proportion of sex practices between time periods. Results Of the 1187 who commenced the survey, 965 (81.3%) completed it. Overall, 70% were female and 66.3% were aged 18–29 years. Most (53.5%) reported less sex during lockdown than in 2019. Compared with 2019, participants were more likely to report sex with a spouse (35.3% vs 41.7%; diff=6.4%; 95% CI 3.6 to 9.2) and less likely to report sex with a girl/boyfriend (45.1% vs 41.8%; diff=−3.3%; 95% CI −7.0 to -0.4) or with casual hook-up (31.4% vs 7.8%; 95% CI −26.9 to -19.8). Solo sex activities increased; 14.6% (123/840) reported using sex toys more often and 26.0% (218/838) reported masturbating more often. Dating app use decreased during lockdown compared with 2019 (42.1% vs 27.3%; diff= −14.8%; 95% CI −17.6 to -11.9). Using dating apps for chatting/texting (89.8% vs 94.5%; diff=4.7%; 95% CI 1.0 to 8.5) and for setting up virtual dates (2.6% vs 17.2%; diff=14.6%; 95% CI 10.1 to 19.2) increased during lockdown. Conclusion Although significant declines in sexual activity during lockdown were reported, people did not completely stop engaging in sexual activities, highlighting the importance of ensuring availability of normal sexual and reproductive health services during global emergencies.

29 January 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
FKFabian Yuh Shiong Kong
Fabian Yuh Shiong Kong
STSepehr N. Tabrizi
Sepehr N. Tabrizi
CFChristopher Kincaid Fairley
Christopher Kincaid Fairley
LVLenka A. Vodstrcil
Lenka A. Vodstrcil
WHWilhelmina Huston
Wilhelmina Huston
JHJane S. Hocking
Jane S. Hocking
There are increasing concerns about treatment failure following treatment for rectal chlamydia with 1 g of azithromycin. A systematic review and meta-analysis was conducted to investigate the efficacy of 1 g of azithromycin as a single dose or 100 mg of doxycycline twice daily for 7 days for the treatment of rectal chlamydia. Medline, Embase, PubMed, Cochrane Controlled Trials Register, Australia New Zealand Clinical Trial Register and ClinicalTrials.gov were searched to the end of April 2014. Studies using 1 g of azithromycin or 7 days of doxycycline for the treatment of rectal chlamydia were eligible. Gender, diagnostic test, serovar, symptomatic status, other sexually transmitted infections, follow-up time, attrition and microbial cure were extracted. Meta-analysis was used to calculate pooled (i) azithromycin and doxycycline efficacy and (ii) efficacy difference. All eight included studies were observational. The random-effects pooled efficacy for azithromycin (based on eight studies) was 82.9% (95% CI 76.0%–89.8%; I2 = 71.0%; P < 0.01) and for doxycycline (based on five studies) was 99.6% (95% CI 98.6%–100%; I2 = 0%; P = 0.571), resulting in a random-effects pooled efficacy difference (based on five studies) of 19.9% (95% CI 11.4%–28.3%; I2 = 48.5%; P = 0.101) in favour of doxycycline. The efficacy of single-dose azithromycin may be considerably lower than 1 week of doxycycline for treating rectal chlamydia. However, the available evidence is very poor. Robust randomized controlled trials are urgently required.

7 March 2011 in Medical Journal of Australia
Verified
Journal Article
Closed access
PDF file
FKFabian Y S Kong
Fabian Y S Kong
RGRebecca J Guy
Rebecca J Guy
JHJane S Hocking
Jane S Hocking
TMTony Merritt
Tony Merritt
MPMarie Pirotta
Marie Pirotta
FBFracp Margaret E Hellard Mb Bs
Fracp Margaret E Hellard Mb Bs
Objective: To describe the proportion of 16–29‐year‐olds tested for chlamydia by Australian general practitioners in a 12‐month period. Design and setting: Between October 2007 and September 2008, the national chlamydia testing rate in 16–29‐year‐olds was calculated by dividing the number of Medicare‐reimbursed chlamydia tests by two denominators: (i) Medicare‐reimbursed GP consultations; and (ii) estimated resident populations adjusted for the proportion who were sexually active. Main outcome measures: GP chlamydia testing rates in 16–29‐year‐olds per 100 patients attending a GP consultation and per 100 sexually active population, by patient age and sex, state/territory of residence, and remoteness area. Results: Among the estimated Australian population of 16–29‐year‐olds, 85.6% of females and 64.4% of males had at least one GP consultation in the 12‐month period. The national GP chlamydia testing rate per 100 patients was 8.9% (95% CI, 8.88%–8.94%). The national GP chlamydia testing rate per 100 sexually active population was 8.0% (95% CI, 7.92%–7.98%). The rate per 100 sexually active population was higher in females (12.5%) compared with males (3.7%) (P < 0.01); higher in 20–24‐year‐olds (9.0%) compared with 16–19‐year‐olds (8.7%) and 25–29‐year‐olds (6.6%) (P < 0.01); higher in those living in non‐metropolitan areas (11.0%) compared with metropolitan areas (8.4%) (P < 0.01); and highest in those living in the Northern Territory (21.4%) compared with other jurisdictions (P < 0.01). Conclusions: Despite clinical guidelines recommending annual chlamydia testing for sexually active 15–29‐year‐olds, our analysis showed that a high proportion of young people aged 16–29 years attend a GP each year, but few of the sexually active population in this age group were tested for chlamydia in general practice. Strategies are needed to support GPs to enhance chlamydia testing in young people.

29 July 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
FKFabian Yuh Shiong Kong
Fabian Yuh Shiong Kong
JHJane Simone Hocking
Jane Simone Hocking
While true antimicrobial resistance to Chlamydia trachomatis is a rare occurrence, repeat chlamydia infections continue to be reported following treatment with a single 1 g dose of azithromycin or week long doxycycline – with considerable more concern about azithromycin treatment failure. While most repeat positive cases are likely to be reinfections, emerging evidence indicates treatment failure may play a role. Current data suggests that there may are differences in the efficacy of the drugs between rectal and non-rectal sites of infection and factors such as immune response, drug pharmacokinetics, organism load, auto-inoculation from rectum to cervix in women and the genital microbiome may play a role in treatment failure. Other possible reasons for repeat infection include the low discriminatory power of NAAT tests to differentiate between viable and nonviable organisms and failure to detect LGV infection. This review will present the current evidence regarding the management challenges for urogenital and anorectal chlamydia infections and provide some suggestions for where future research efforts are needed to address important knowledge gaps in this area and provide stronger evidence for the development of robust treatment guidelines.

2 May 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
FKFabian Yuh Shiong Kong
Fabian Yuh Shiong Kong
CKChris Kenyon
Chris Kenyon
MUMagnus Unemo
Magnus Unemo
Rates of sexually transmitted infections (STIs) continue to rise across the world and interventions are essential to reduce their incidence. Past and recent studies have indicated this may be achieved using doxycycline post-exposure prophylaxis (PEP) and this has sparked considerable interest in its use. However, many unanswered questions remain as to its long-term effects and particularly potentially negative impact on human microbiomes and antimicrobial resistance among STIs, other pathogens, and commensals. In this review, we discuss seven areas of concern pertaining to the widespread use of doxycycline PEP.